Tiger Brokers

BUZZ-AbbVie rises after licensing deal for cancer treatment with India's Glenmark Pharma unit

Reuters
Jul 10, 2025
BUZZ-AbbVie rises after licensing deal for cancer treatment with India's Glenmark Pharma unit

** Shares of drugmaker AbbVie ABBV.N rise 2.3% to $194.90

** AbbVie and India's Glenmark Pharmaceuticals arm GLEN.NS Ichnos Glenmark Innovation $(IGI)$ have signed an exclusive licensing agreement for IGI's cancer treatment, adding to the U.S. firm's oncology portfolio

** AbbVie will get exclusive rights to develop, manufacture and commercialize IGI's ISB 2001 in North America, Europe, Japan and Greater China

** IGI's experimental drug, ISB 2001, is currently in early-stage trial in patients with relapsed or refractory multiple myeloma, a type of cancer that develops in white blood cells

** IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in additional milestone payments

** Including session moves, ABBV is up 9.8% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10